目的 系统评价拉莫三嗪单药治疗儿童癫癎的有效性和安全性。方法 计算机检索PubMed、Cochrane 图书馆、CNKI、VIP、CBM、万方等中英文数据库，获得拉莫三嗪单药治疗儿童癫癎的随机对照试验。应用Cochrane 协作网推荐的方法进行文献筛选，资料提取和文献质量评估，采用RevMan 5.2软件进行Meta分析。结果 共纳入9个RCTs （1016例）。拉莫三嗪的癫癎发作完全控制率明显低于乙琥胺，与卡马西平和丙戊酸钠的差异均无统计学意义。拉莫三嗪的不良反应发生率明显低于卡马西平，与丙戊酸钠和乙琥胺的差异均无统计学意义；3种药物的退出率比较差异无统计学意义。结论 对于传统抗癫癎药物治疗无效、不良反应明显患儿，拉莫三嗪是一种较为理想的替代药物。但仍有待高质量、大样本及较长随访时间的随机对照试验予以证实。
Abstract
Objective To investigate the efficacy and safety of lamotrigine monotherapy in children with epilepsy via a systematic review. Methods PubMed, Cochrane, CNKI, VIP, CBM, Wanfang Data were searched for randomized controlled trials (RCTs) of lamotrigine monotherapy in children with epilepsy. Literature screening, data extraction, and quality assessment were performed according to the method recommended by Cochrane Collaboration. RevMan 5.2 software was used to conduct the Meta analysis. Results A total of 9 RCTs involving 1 016 participants were included. Lamotrigine yielded a significantly lower complete control rate of seizure than ethosuximide, but the complete control rate of seizure showed no significant differences between lamotrigine and carbamazepine/sodium valproate. Patients treated with lamotrigine had a significantly lower incidence rate of adverse events than those treated with carbamazepine, but the incidence rate of adverse events showed no significant differences between patients treated with lamotrigine and sodium valproate/carbamazepine. The drop-out rate showed no significant differences between the three treatment groups. Conclusions Lamotrigine is an ideal alternative drug for children who do not respond to traditional antiepileptic medication or experience significant adverse reactions; however, more high-quality RCTs with a large sample size and a long follow-up time are needed to confirm these conclusions.
关键词
拉莫三嗪 /
单药治疗 /
癫癎 /
系统评价 /
Meta 分析 /
儿童
Key words
Lamotrigine /
Monotherapy /
Epilepsy /
Systematic review /
Meta analysis /
Child
{{custom_sec.title}}
{{custom_sec.title}}
{{custom_sec.content}}
参考文献
[1] 吴江. 神经病学[M]// 北京: 人民卫生出版社. 2005: 264-281.
[2] World Health Organization. Epilepsy. Fact sheet N°999, World Health Organization[EB/OL]. (October, 2012). http://www.who. int/mediacentre/factsheets/fs999/en/index.html.
[3] World Health Organization. Epilepsy Management at Primary Health Level in rural China[EB/OL]. (March, 2009). http:// www.who.int/mental_health/neurology/epilepsy_china_report_ english.pdf.
[4] 李雪华. 癫癎的治疗方法研究进展[J]. 临床合理用药, 2012, 5(6): 155.
[5] 李世绰, 吴立文. 中华医学会. 临床诊疗指南——癫癎病分册[M]. 北京: 人民卫生出版社, 2007: 48-50.
[6] Sitges M, Guameros A, Nekrassov V, et al. Effects of carbamazeping, phenytion, valproic acid, oxcarbazepine, lamotrigine, topiramate and vinpoceting on the presynaptic Ca2+ channel-mediated release of [3H] glutamate: Comparison with the Na+ channel-mediated release[J]. Neuropharmacology, 2007, 53(7): 854-862.
[7] Stefani A, Spadoni F, SiniscalchiA, et a1. Lamotrigine inhibits Ca2+ currents in cortical neurons: functional implications[J]. Eur J Pharmacol, 2006, 307(1): 113-116.
[8] 拉莫三嗪药品说明书. 2011 年版. GlaxoSmithKline Pharmaceuticals S.A.
[9] Wheless JW, Clarke DF, ArzimanoglouA, et al. Treatment of pediatric epilepsy: European expert opinion, 2007[J]. Epileptic Disord, 2007, 9(4): 353-412.
[10] 宋春杰, 陈惠玲, 王小勇. 拉莫三嗓添加或单药治疗部分发作性癫癎的有效性和耐受性研究[J]. 中国神经免疫学和神经病学杂志, 2009, 16(5): 344-347.
[11] Higggins JPT, Green S. Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0 [updated March 2011]. Available at: http://www.cochrane-handbook.org/: The CochraneCollaboration, 2011.
[12] National Institute of Health. National Cancer Institute. Common Terminology Criteria for Adverse Events, Version 4.3. Available from: http://evs.nci.nih.gov/ftp1/CTCAE/about.html.
[13] 张言春. 拉莫三嗪治疗儿童失神癫癎的疗效研究[J]. 中国社区医师( 医学专业), 2012, 14(27): 101.
[14] 刘俊. 拉莫三嗪及丙戊酸钠对癫癎患儿血脂的影响[J]. 实用临床医药杂志, 2011, 15(19): 133-135.
[15] 李冠慧, 庞桂香, 王荣, 等. 拉莫三嗪和丙戊酸钠治疗典型失神发作疗效比较[J]. 中国实用儿科杂志, 2008, 23(7): 549-550.
[16] 黄铁栓, 朱金兰, 李冰, 等. 丙戊酸和拉莫三嗪治疗儿童失神癫癎的临床研究[J]. 中国当代儿科杂志, 2009, 11(8): 653-655.
[17] Biton V, Levisohn P, Hoyler S, et al. Lamotrigine versus valproate monotherapy-associated weight change in adolescents with epilepsy: results from a post hoc analysis of a randomized, double-blind clinical trial[J]. Journals of Child Neurology, 2003, 18(2): 133-139.
[18] Coppola G, AuricchioG, Federico R, et al. Lamotrigine versus valproic acid as first-line monotherapy in newly diagnosed typical absence seizures: an open-label, randomized, parallelgroup study[J]. Epilepsia, 2004, 45(9): 1049-1053.
[19] Eun SH, Eun BL, Lee JS. Effects of lamotrigine on cognition and behavior compared to carbamazepine as monotherapy for children with partial epilepsy[J]. Brain & Development, 2012, 34(10): 818-823.
[20] Nieto-Barrera M, Brozmanova M, Capovilla G. A comparison of monotherapy with lamotrigine or carbamazepine in patients with newly diagnosed partial epilepsy[J]. Epilepsy Research, 2001, 46(2): 145-155.
[21] Glause TA, Cnaan A, ShinnarS. Ethosuximide, valproic acid, and lamotrigine in childhood absence epilepsy: Initial monotherapy outcomes at 12 months[J]. Epilepsia, 2013, 54(1): 141-155.
[22] Commission on antiepileptic drugs. Considerations on designing clinical trials toevaluate the place of new antiepileptic drugs in the treatment of newly diagnosed and chronic patients with epilepsy[J]. Epilepsia, 1998: 39(7): 799-803.
基金
国家自然科学基金中国儿童合理用药评价指标体系的循证研究（81373381）。
PDF(1424 KB)
